Literature DB >> 1700936

The effects of a new immunosuppressive agent, FK506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis.

S Hara1, A Fukatsu, N Suzuki, N Sakamoto, S Matsuo.   

Abstract

The aim of the present work was to study the effects of a new immunosuppressive drug, FK506, in accelerated nephrotoxic serum glomerulonephritis. Glomerulonephritis was induced in female Wistar rats by the preimmunization with normal rabbit IgG (Day-4) and the subsequent intravenous injection of rabbit anti-GBM serum (Day 0). Without treatment with FK506, rats developed proteinuria at Day 6 and onward. Rat anti-rabbit IgG was strongly detected at Day 6 and the titer was maintained through Day 20. Moderate hypercellularity and focal crescent formation were observed at Day 20. Rats injected intramuscularly with 0.3 or 1 mg/kg of FK506 did not develop proteinuria and the anti-rabbit IgG titer was much less or was undetectable throughout the experiments. These data suggest that FK506 is effective in the present model of glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700936     DOI: 10.1016/0090-1229(90)90110-c

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  3 in total

Review 1.  FK 506 and autoimmune disease: perspective and prospects.

Authors:  A W Thomson; T E Starzl
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

Review 2.  FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.

Authors:  A W Thomson; P B Carroll; J McCauley; J Woo; K Abu-Elmagd; T E Starzl; D H Van Thiel
Journal:  Springer Semin Immunopathol       Date:  1993

3.  The role of C5a in the development of thrombotic glomerulonephritis in rats.

Authors:  C Kondo; M Mizuno; K Nishikawa; Y Yuzawa; N Hotta; S Matsuo
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.